vs
阿特拉斯·科普柯（AESI）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
阿特拉斯·科普柯的季度营收约是Ultragenyx Pharmaceutical Inc.的1.2倍（$249.4M vs $207.3M），阿特拉斯·科普柯净利率更高（-8.9% vs -62.0%，领先53.1%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs -8.1%），阿特拉斯·科普柯自由现金流更多（$-18.1M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 13.8%）
阿特拉斯·科普柯集团是瑞典跨国工业企业，生产压缩机、真空设备、泵、发电机、装配工具、质量检测设备等工业应用及移动发电领域的产品与系统，业务覆盖全球约180个国家。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
AESI vs RARE — 直观对比
营收规模更大
AESI
是对方的1.2倍
$207.3M
营收增速更快
RARE
高出34.0%
-8.1%
净利率更高
AESI
高出53.1%
-62.0%
自由现金流更多
AESI
多$82.7M
$-100.8M
两年增速更快
RARE
近两年复合增速
13.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $249.4M | $207.3M |
| 净利润 | $-22.2M | $-128.6M |
| 毛利率 | 8.1% | — |
| 营业利润率 | -6.0% | -54.7% |
| 净利率 | -8.9% | -62.0% |
| 营收同比 | -8.1% | 25.9% |
| 净利润同比 | -254.5% | 3.5% |
| 每股收益（稀释后） | $-0.19 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AESIRARE
| Q4 25 | $249.4M | $207.3M | ||
| Q3 25 | $259.6M | $159.9M | ||
| Q2 25 | $288.7M | $166.5M | ||
| Q1 25 | $297.6M | $139.3M | ||
| Q4 24 | $271.3M | $164.6M | ||
| Q3 24 | $304.4M | $139.5M | ||
| Q2 24 | $287.5M | $147.0M | ||
| Q1 24 | $192.7M | $108.8M |
净利润AESIRARE
| Q4 25 | $-22.2M | $-128.6M | ||
| Q3 25 | $-23.7M | $-180.4M | ||
| Q2 25 | $-5.6M | $-115.0M | ||
| Q1 25 | $1.2M | $-151.1M | ||
| Q4 24 | $14.4M | $-133.2M | ||
| Q3 24 | $3.9M | $-133.5M | ||
| Q2 24 | $14.8M | $-131.6M | ||
| Q1 24 | $26.8M | $-170.7M |
毛利率AESIRARE
| Q4 25 | 8.1% | — | ||
| Q3 25 | 9.2% | — | ||
| Q2 25 | 18.1% | — | ||
| Q1 25 | 18.3% | — | ||
| Q4 24 | 18.4% | — | ||
| Q3 24 | 17.4% | — | ||
| Q2 24 | 21.0% | — | ||
| Q1 24 | 35.7% | — |
营业利润率AESIRARE
| Q4 25 | -6.0% | -54.7% | ||
| Q3 25 | -7.1% | -106.9% | ||
| Q2 25 | 2.5% | -64.8% | ||
| Q1 25 | 5.2% | -102.6% | ||
| Q4 24 | 11.3% | -74.3% | ||
| Q3 24 | 5.0% | -94.6% | ||
| Q2 24 | 9.8% | -79.1% | ||
| Q1 24 | 20.6% | -151.9% |
净利率AESIRARE
| Q4 25 | -8.9% | -62.0% | ||
| Q3 25 | -9.1% | -112.8% | ||
| Q2 25 | -1.9% | -69.0% | ||
| Q1 25 | 0.4% | -108.5% | ||
| Q4 24 | 5.3% | -80.9% | ||
| Q3 24 | 1.3% | -95.7% | ||
| Q2 24 | 5.2% | -89.5% | ||
| Q1 24 | 13.9% | -156.8% |
每股收益（稀释后）AESIRARE
| Q4 25 | $-0.19 | $-1.28 | ||
| Q3 25 | $-0.19 | $-1.81 | ||
| Q2 25 | $-0.04 | $-1.17 | ||
| Q1 25 | $0.01 | $-1.57 | ||
| Q4 24 | $0.12 | $-1.34 | ||
| Q3 24 | $0.04 | $-1.40 | ||
| Q2 24 | $0.13 | $-1.52 | ||
| Q1 24 | $0.26 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $421.0M |
| 总债务越低越好 | $604.2M | — |
| 股东权益账面价值 | $1.2B | $-80.0M |
| 总资产 | $2.2B | $1.5B |
| 负债/权益比越低杠杆越低 | 0.50× | — |
8季度趋势，按日历期对齐
现金及短期投资AESIRARE
| Q4 25 | — | $421.0M | ||
| Q3 25 | — | $202.5M | ||
| Q2 25 | — | $176.3M | ||
| Q1 25 | — | $127.1M | ||
| Q4 24 | — | $174.0M | ||
| Q3 24 | — | $150.6M | ||
| Q2 24 | — | $480.7M | ||
| Q1 24 | — | $112.3M |
总债务AESIRARE
| Q4 25 | $604.2M | — | ||
| Q3 25 | $529.1M | — | ||
| Q2 25 | $533.8M | — | ||
| Q1 25 | $538.5M | — | ||
| Q4 24 | $0 | — | ||
| Q3 24 | $180.0M | — | ||
| Q2 24 | $180.0M | — | ||
| Q1 24 | $180.0M | — |
股东权益AESIRARE
| Q4 25 | $1.2B | $-80.0M | ||
| Q3 25 | $1.2B | $9.2M | ||
| Q2 25 | $1.3B | $151.3M | ||
| Q1 25 | $1.3B | $144.2M | ||
| Q4 24 | $1.0B | $255.0M | ||
| Q3 24 | $1.0B | $346.8M | ||
| Q2 24 | $1.1B | $432.4M | ||
| Q1 24 | $1.1B | $140.3M |
总资产AESIRARE
| Q4 25 | $2.2B | $1.5B | ||
| Q3 25 | $2.2B | $1.2B | ||
| Q2 25 | $2.2B | $1.3B | ||
| Q1 25 | $2.3B | $1.3B | ||
| Q4 24 | $2.0B | $1.5B | ||
| Q3 24 | $2.0B | $1.5B | ||
| Q2 24 | $2.0B | $1.6B | ||
| Q1 24 | $1.9B | $1.3B |
负债/权益比AESIRARE
| Q4 25 | 0.50× | — | ||
| Q3 25 | 0.43× | — | ||
| Q2 25 | 0.42× | — | ||
| Q1 25 | 0.41× | — | ||
| Q4 24 | 0.00× | — | ||
| Q3 24 | 0.17× | — | ||
| Q2 24 | 0.17× | — | ||
| Q1 24 | 0.17× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $3.7M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $-18.1M | $-100.8M |
| 自由现金流率自由现金流/营收 | -7.3% | -48.6% |
| 资本支出强度资本支出/营收 | 8.7% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-30.9M | $-472.0M |
8季度趋势，按日历期对齐
经营现金流AESIRARE
| Q4 25 | $3.7M | $-99.8M | ||
| Q3 25 | $32.4M | $-91.4M | ||
| Q2 25 | $88.6M | $-108.3M | ||
| Q1 25 | $-7.5M | $-166.5M | ||
| Q4 24 | $70.9M | $-79.3M | ||
| Q3 24 | $85.2M | $-67.0M | ||
| Q2 24 | $60.9M | $-77.0M | ||
| Q1 24 | $39.6M | $-190.7M |
自由现金流AESIRARE
| Q4 25 | $-18.1M | $-100.8M | ||
| Q3 25 | $-1.4M | $-92.7M | ||
| Q2 25 | $48.4M | $-110.7M | ||
| Q1 25 | $-59.8M | $-167.8M | ||
| Q4 24 | $-5.6M | $-79.5M | ||
| Q3 24 | $-1.1M | $-68.6M | ||
| Q2 24 | $-54.9M | $-79.0M | ||
| Q1 24 | $-55.9M | $-193.9M |
自由现金流率AESIRARE
| Q4 25 | -7.3% | -48.6% | ||
| Q3 25 | -0.5% | -58.0% | ||
| Q2 25 | 16.8% | -66.5% | ||
| Q1 25 | -20.1% | -120.5% | ||
| Q4 24 | -2.1% | -48.3% | ||
| Q3 24 | -0.4% | -49.2% | ||
| Q2 24 | -19.1% | -53.7% | ||
| Q1 24 | -29.0% | -178.2% |
资本支出强度AESIRARE
| Q4 25 | 8.7% | 0.5% | ||
| Q3 25 | 13.0% | 0.8% | ||
| Q2 25 | 13.9% | 1.5% | ||
| Q1 25 | 17.6% | 1.0% | ||
| Q4 24 | 28.2% | 0.1% | ||
| Q3 24 | 28.3% | 1.2% | ||
| Q2 24 | 40.3% | 1.4% | ||
| Q1 24 | 49.6% | 3.0% |
现金转化率AESIRARE
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -6.11× | — | ||
| Q4 24 | 4.92× | — | ||
| Q3 24 | 21.74× | — | ||
| Q2 24 | 4.10× | — | ||
| Q1 24 | 1.48× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AESI
| Services | $126.2M | 51% |
| Products | $105.2M | 42% |
| Moser Acquisition | $18.1M | 7% |
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
